<DOC>
	<DOCNO>NCT01673698</DOCNO>
	<brief_summary>The REDUCE Pivotal Trial pivotal clinical study design develop valid scientific evidence regard safety effectiveness ReShape Duo® adjunct diet exercise treatment obese subject one obesity-related comorbid condition .</brief_summary>
	<brief_title>A Prospective , Randomized Multicenter Study Evaluate Safety Efficacy ReShape Duo™ Intragastric Balloon System Obese Subjects</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : Patients 21 60 year age Body Mass Index ( BMI ) ≥ 30 kg/m^2 ≤ 40 kg/m^2 At least 5 year obesity ( BMI ≥ 30 ) Stable weight , define subject gain lose ≥ 5 % body weight 3 month precede screen assessment Failure lose weight , within 36 month precede screen date , participation either following : 1 . A medically commercially supervised weight loss program involve regular counseling regard diet exercise . 2 . Use United States Food Drug Administration ( FDA ) approve diet drug The presence one obesityrelated comorbid condition Willing able provide Informed Consent Willing able comply study procedure visit schedule specify protocol If female , patient must 1. postmenopausal least 1 year OR 2. surgically sterile , OR 3. child bear potential , must practice birth control , willing avoid pregnancy year study participation , negative serum pregnancy test screening , negative urine pregnancy test baseline Residing within reasonable distance Investigator 's treat office able willing travel Investigator 's office complete routine followup visit . Exclusion criterion : History and/or ongoing clinically significant condition disorder gastrointestinal ( GI ) tract Clinically significant uncontrolled/unstable hepatic , reproductive , gastrointestinal , renal , hematologic , pulmonary , neurologic , psychiatric , respiratory , endocrine , cardiovascular system diseases Significant acute and/or chronic infection kind . Severe coagulopathy , hepatic insufficiency cirrhosis Uncontrolled severe asthma , asthma require likely require inhale steroid therapy anticipate duration trial participation Severe obstructive sleep apnea Incompletely control hypothyroidism hyperthyroidism Severe systemic disease [ consistent ASA ( American Society Anesthesia ) Physical Status Classification Score 3 great ] Eating disorder , especially binge eat Inability walk 200 yard without assistance Known allergies device material accessory , i.e . silicone , methylene blue , corn starch Active drug alcohol addiction within 12 month enrollment Insulindependent diabetes ( either Type 1 Type 2 ) significant likelihood require insulin treatment follow 12 month Depressive disorder total Beck Depression Inventory ( BDI ) score &gt; 16 point , and/or BDI affective subscale score &gt; 7 point screen Ongoing treatment , anticipate need treatment , anticoagulant , know gastric irritant aspirin ( ASA ) nonsteroidal antiinflammatory drug ( NSAIDs ) agent promote gastrointestinal bleeding , within 1 month prior enrollment , unwillingness forego medication study period Participation within 60 day screen date previous ongoing clinical trial current usage investigational drug device Any use intragastric device prior study . Genetically cause obesity , PraderWilli syndrome Any prior bariatric surgery likely undergo bariatric surgery study followup period Concomitant use , unwillingness avoid use , weight loss medication , weight loss supplement , weight loss herbal preparation and/or participation nonstudyrelated organized weight loss program ( commercial medical ) time study , include online smart phone application track modify food intake , exercise regimen weight Chronic opiate use ( &gt; 3 month continuous use ) likely need opiate use study participation Contraindication allergy , unwillingness use , proton pump inhibitor medication throughout study followup durationPregnancy , breast feeding , intention become pregnant study Any screen laboratory value outside normal range deem clinically significant Investigator Anemia define either : 1 . Hemoglobin ( Hgb ) value females &lt; 11.0 g/dl , male &lt; 12.0 g/dl 2 . Abnormal red cell index iron deficiency Smoking cessation within 3 month study entry plan quit smoke study Major surgery , open biopsy significant traumatic injury within 3 month prior enrollment . History significant adverse experience sedation anesthesia Serious uncontrolled psychiatric illness disorder could compromise patient understand compliance study procedures Any condition , opinion Investigator , would compromise wellbeing patient study prevent patient meeting perform study requirement , include : 1 . Inability unwillingness sign patient inform consent document . 2 . Inability participate necessary study activity due physical mental limitation . 3 . Inability unwillingness return require followup visit . Employees/family member ReShape Medical® affiliate contractor Employees/family member Investigator , subInvestigators , medical office practice , surgical , bariatric hospital organization study procedure may perform An immediate family member ( marriage blood relationship ) another subject already enrol REDUCE Pivotal Trial Endoscopic exclusion criterion : Peptic ulceration Clinically significant hiatal hernia ( &gt; 3 cm ) Patulous pyloric channel Erosive esophagitis Varices Angiectasias Barrett 's esophagus Esophageal stricture Gastric mass Any subject characteristic would prevent successful insertion ReShape Duo™ opinion Investigator preclude safe use ReShape Duo™</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>obesity</keyword>
	<keyword>weight loss</keyword>
</DOC>